Predictors and the subsequent risk of end-stage renal disease - Usefulness of 30% decline in estimated GFR over 2 years

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Chang, Wen Xiu ^a,b   Asakawa, Shinichiro ^a   Toyoki, Daigo ^a   Nemoto, Yoshikazu ^a   Morimoto, Chikayuki ^a   Tamura, Yoshifuru ^a   Ota, Tatsuru ^a   Shibata, Shigeru ^a   Fujigaki, Yoshihide ^a   Shen, Zhong Yang ^b   Uchida, Shunya ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b TIANJIN FIRST CENTRAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHORUS; SERUM ALBUMIN; URIC ACID;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DETERIORATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; AGED; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; ROC CURVE; TIME FACTORS; YOUNG ADULT;

EID: 84941354694     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132927     Document Type: Article

References (37)

1. Yang W, Xie D, Anderson AH, Joffe MM, Greene T, Teal V, et al. Association of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis. 2014; 63: 236-243. doi: 10.1053/j.ajkd.2013.08.028 PMID: 24182662
2. Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, et al. Short-term change in kidney function and risk of end-stage renal disease. Nephrol Dial Transplant. 2012; 27: 3835-3843. doi: 10.1093/ndt/gfs263 PMID: 22764191
3. Portoles J, Gorriz JL, Rubio E, de Alvaro F, Garcia F, Alvarez-Chivas V, et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013; 14: 2. doi: 10.1186/1471-2369-14-2 PMID: 23295149
4. Van Pottelbergh G, Bartholomeeusen S, Buntinx F, Degryse J. The evolution of renal function and the incidence of end-stage renal disease in patients aged >/= 50 years. Nephrol Dial Transplant. 2012; 27: 2297-2303. doi: 10.1093/ndt/gfr659 PMID: 22102615
5. Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One. 2012; 7: e38904. doi: 10.1371/journal.pone.0038904 PMID: 22719981
6. Ni Z, Yuan Y, Wang Q, Cao L, Che X, Zhang M, et al. Time-averaged albumin predicts the long-term prognosis of IgA nephropathy patients who achieved remission. J Transl Med. 2014; 12: 194. doi: 10.1186/1479-5876-12-194 PMID: 25011573
7. Nacak H, van Diepen M, de Goeij MC, Rotmans JI, Dekker FW, PREPARE-2 study group. Uric acid: association with rate of renal function decline and time until start of dialysis in incident pre-dialysis patients. BMC Nephrol. 2014; 15: 91. doi: 10.1186/1471-2369-15-91 PMID: 24939671
8. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009; 20: 2075-2084. doi: 10.1681/ASN.2008111205 PMID: 19608703
9. Cancela AL, Santos RD, Titan SM, Goldenstein PT, Rochitte CE, Lemos PA, et al. Phosphorus is associated with coronary artery disease in patients with preserved renal function. PLoS One. 2012; 7: e36883. doi: 10.1371/journal.pone.0036883 PMID: 22590632
10. Rahman M, Yang W, Akkina S, Alper A, Anderson AH, Appel LJ, et al. Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clin J Am Soc Nephrol. 2014; 9: 1190-1198. doi: 10.2215/CJN.09320913 PMID: 24832097
11. Zhuo L, Zou G, Li W, Lu J, Ren W. Prevalence of diabetic nephropathy complicating non-diabetic renal disease among Chinese patients with type 2 diabetes mellitus. Eur J Med Res. 2013; 18: 4. doi: 10.1186/2047-783X-18-4 PMID: 23432977
12. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63: 713-735. doi: 10.1053/j.ajkd.2014.01.416 PMID: 24647050
13. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012; 60: 850-886. doi: 10.1053/j.ajkd.2012.07.005 PMID: 23067652
14. Hoefield RA, Kalra PA, Baker P, Lane B, New JP, O'Donoghue DJ, et al. Factors associated with kidney disease progression and mortality in a referred CKD population. Am J Kidney Dis. 2010; 56: 1072-1081. doi: 10.1053/j.ajkd.2010.06.010 PMID: 20692750
15. Johnson ES, Smith DH, Thorp ML, Yang X, Juhaeri J. Predicting the risk of end-stage renal disease in the population-based setting: a retrospective case-control study. BMC Nephrol. 2011; 12: 17. doi: 10.1186/1471-2369-12-17 PMID: 21545746
16. Erickson KF, Lea J, McClellan WM. Interaction between GFR and risk factors for morbidity and mortality in African Americans with CKD. Clin J Am Soc Nephrol. 2013; 8: 75-81. doi: 10.2215/CJN.03340412 PMID: 23085727
17. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329: 1456-1462. PMID: 8413456
18. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014; 311: 2518-2531. PMID: 24892770
19. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982-992. doi: 10.1053/j.ajkd.2008.12.034 PMID: 19339088
20. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011; 305: 1553-1559. doi: 10.1001/jama. 2011.451 PMID: 21482743
21. George B, Seals S, Aban I. Survival analysis and regression models. J Nucl Cardiol. 2014; 21: 686-694. doi: 10.1007/s12350-014-9908-2 PMID: 24810431
22. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143: 29-36. PMID: 7063747
23. Bantis LE, Nakas CT, Reiser B. Construction of confidence regions in the ROC space after the estimation of the optimal Youden index-based cut-off point. Biometrics. 2014; 70: 212-223. doi: 10.1111/biom.12107 PMID: 24261514
24. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006; 17: 2974-2984. PMID: 17035611
25. Zoja C, Abbate M, Remuzzi G. Progression of renal injury toward interstitial inflammation and glomerular sclerosis is dependent on abnormal protein filtration. Nephrol Dial Transplant. 2015; 30: 706-712. doi: 10.1093/ndt/gfu261 PMID: 25087196
26. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006; 17: 17-25. PMID: 16291837
27. Shoji K, Tanaka T, Nangaku M. Role of hypoxia in progressive chronic kidney disease and implications for therapy. Curr Opin Nephrol Hypertens. 2014; 23: 161-168. doi: 10.1097/01.mnh.0000441049. 98664.6c PMID: 24378776
28. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084. PMID: 17108342
29. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-2032. doi: 10.1056/NEJMoa0907845 PMID: 19880844
30. Covic A, Nistor I, Donciu MD, Dumea R, Bolignano D, Goldsmith D. Erythropoiesis-Stimulating Agents (ESA) for Preventing the Progression of Chronic Kidney Disease: A Meta-Analysis of 19 Studies. Am J Nephrol. 2014; 40: 263-279. doi: 10.1159/000366025 PMID: 25323019
31. Varshney A, Rehan M, Subbarao N, Rabbani G, Khan RH. Elimination of endogenous toxin, creatinine from blood plasma depends on albumin conformation: site specific uremic toxicity & impaired drug binding. PLoS One. 2011; 6: e17230. doi: 10.1371/journal.pone.0017230 PMID: 21386972
32. Steinman TI. Serum albumin: its significance in patients with ESRD. Semin Dial. 2000; 13: 404-408. PMID: 11130266
33. Inoue T, Ikeda H, Nakamura T, Abe S, Taguchi I, Kikuchi M, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET). Intern Med. 2011; 50: 1273-1278. PMID: 21673461
34. Bouma-de Krijger A, Bots ML, Vervloet MG, Blankestijn PJ, Ter Wee PW, van Zuilen AD, et al. Timeaveraged level of fibroblast growth factor-23 and clinical events in chronic kidney disease. Nephrol Dial Transplant. 2014; 29: 88-97. doi: 10.1093/ndt/gft456 PMID: 24215017
35. Sim JJ, Bhandari SK, Smith N, Chung J, Liu IL, Jacobsen SJ, et al. Phosphorus and risk of renal failure in subjects with normal renal function. Am J Med. 2013; 126: 311-318. doi: 10.1016/j.amjmed.2012. 08.018 PMID: 23375678
36. Seiler S, Lucisano G, Ege P, Fell LH, Rogacev KS, Lerner-Graber A, et al. Single FGF-23 measurement and time-averaged plasma phosphate levels in hemodialysis patients. Clin J Am Soc Nephrol. 2013; 8: 1764-1772. doi: 10.2215/CJN.13021212 PMID: 23846463
37. Torlen K, Kalantar-Zadeh K, Molnar MZ, Vashistha T, Mehrotra R. Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort. Clin J Am Soc Nephrol. 2012; 7: 1272-1284. doi: 10.2215/CJN.00960112 PMID: 22626960